• Explore /
  • Poster
  • / Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.

Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.

Abstract Poster

Authors

null

Howard Colman

Hunstman Cancer Institute, Salt Lake City, UT

Howard Colman , Jeffrey J. Raizer , Tobias Walbert , Scott Randall Plotkin , Marc C. Chamberlain , Eric T. Wong , Vinay K. Puduvalli , David A. Reardon , Fabio Massaiti Iwamoto , Maciej M. Mrugala , Brett Johnson , Karthik Sonty , David Alan Karlin , Michael Pelayo , Marguerite Hutchinson , Henry Hsu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT01790503

Citation

J Clin Oncol 36, 2018 (suppl; abstr 2015)

DOI

10.1200/JCO.2018.36.15_suppl.2015

Abstract #

2015

Poster Bd #

173

Abstract Disclosures

Similar Posters

First Author: Manmeet Singh Ahluwalia

First Author: Lindsay J Lipinski

Poster

2020 ASCO Virtual Scientific Program

Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.

Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.

First Author: Wenyin Shi

First Author: V. Verschaeve